Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female pediatric ESRD, Patients \>_ 2 and \<_ 16 years of age, whose legally authorized representative provided signed informed consent.~* Stabilized on chronic hemodialysis therapy with an identified need for maintenance iron therapy.~* Predetermined TSAT and serum Ferritin (at the screening visit).~* Receiving a stable EPO dosing regimen.~Exclusion Criteria:~* Receipt of any form of iron supplementation during the 2 weeks prior to the first Ferrlecit dosing.~* Hypersensitivity to Ferrlecit or any of its inactive components.~* High TSAT level.~* High Serum Ferritin

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).